Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO.
Participation in the study will last about 18 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
600 participants in 5 patient groups, including a placebo group
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal